AstraZeneca pays $350m upfront for US, China rights to anemia drug
This article was originally published in Scrip
Executive Summary
AstraZeneca bolstered its pipeline on 31 July with a major licensing deal for a late-stage anemia treatment. It will pay privately held US firm FibroGen upfront and subsequent non-contingent payments of $350 million for FG-4592, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI).